Palbocib (Palbociclib) 125 mg
Palbocib-125 (Palbociclib 125 mg) is a CDK4/6 inhibitor, a class of drugs that has revolutionized the treatment of metastatic breast cancer.
Manufacturer: Aprazer (India). A generic equivalent to Ibrance.
Mechanism ("The Cellular Brake"):
Cancer cells often have overactive CDK4/6 proteins that drive them to divide uncontrollably. Palbociclib blocks these proteins, effectively stopping the cell division cycle. It works synergistically with hormonal therapy to delay disease progression significantly.
✅ Key Benefit: Offers a chemotherapy-free option that maintains quality of life for longer.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 04.03.2026
What Customers Say
No reviews yet
Your review can be the first!